Originally from Barcelona, Dr. Munné gained his Ph.D. in Genetics from the University of Pittsburgh and in 1991, joined Dr. Jacques Cohen at the Cornell University Medical College located in New York City. It was at Cornell, he developed the first Preimplantation Genetic Screening (PGS) test to detect chromosome abnormalities, which resulted in the first PGS babies in 1993, for which he received prizes in 1994 and 1995 by The Society for Assisted Reproductive Technology (SART). Dr. Munné became the Director of Preimplantation Genetic Diagnosis at The Institute for Reproductive Medicine and Science of Saint Barnabas in 1995 where he developed the first test to detect chromosome translocations in human embryos obtaining the SART prize for it in 1996, as well as demonstrating a significant decrease in spontaneous abortions after PGS, which obtained the 1998 prize paper of the Society for Assisted Reproductive Technology. In 2001, Dr. Munné co‐founded Reprogenetics, with Jacques Cohen and David Sable. He directed the company until 2016 and saw its expansion to four continents. In 2011 Dr. Munné co‐founded with Alex Bisignano the genomics company, Recombine. Both Reprogenetics and Recombine were later acquired by CooperSurgical Fertility and Genomic Solutions.

Dr. Munné’s research interests is on the prevention of genetic disease and infertility through pre‐implantation testing of embryos and couples, understanding the impact of chromosome abnormalities in human reproduction, and developing personalized genetic tests for infertility and other conditions. Dr. Munné has published over 200 peer‐reviewed scientific publications, and is a frequent lecturer, both nationally and internationally.  He is co‐founder (2002) and member of the Board of Directors of the Preimplantation Genetic Diagnosis International Society (PGDIS) and served as president and other board of directors positions from 2002‐2014.